This pLSC6 predictive scoring system identifies relapse risk and treatment outcomes in acute myeloid leukemia (AML) patients based on the expression levels of six genes. The persistence of leukemic stem cells (LSC) is the primary cause of acute myeloid leukemia (AML) relapse and drug resistance, the most prevalent forms of treatment failure for both pediatric and adult patients. The standard induction treatment of AML patients involves ara-C (Cytarabine) and daunorubicin and etoposide (ADE standard chemotherapy). Current prognostic tests use a 17-gene panel, highlighting the need for one with increased predictive power, identifying patients at risk for relapse or potential candidates for transplantation.
Researchers at the University of Florida have developed a pLSC6 predictive scoring system for acute myeloid leukemia (AML) based on a six-gene panel. The panel identifies high- or low-risk patients, those who could benefit from transplants or have a potential for disease relapse.
Predicts relapse risk and treatment outcomes in acute myeloid leukemia (AML) patients, aiding in the development of treatment plans
This pLSC6 predictive scoring system uses the gene expression levels of six genes from leukemic cells extracted from patients at diagnosis. RNA transcripts, a set of genes comprising DNMT3B, GPR56, CD34, SOCS2, SPINK2, and FAM30A, and at least one reference gene, are transcribed to produce a set of cDNAs. The amplification products of the cDNAs are quantified to obtain the levels of amplification products in the biological sample, calculating the pLSC6 score and comprising a report. The score aids in determining a prognosis of a cancer patient, such as event-free survival (EFS), overall survival (OS), predicting relapse and treatment outcomes, or assessing whether a patient is a candidate for transplantation therapy.
